Valuation models
price $1,417.54 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused754.88 – 1,243.04943.8550% overvaluedDCF · Perpetuity growth · 10y812.39 – 1,361.671,024.6138% overvaluedDCF · EBITDA exit · 5y998.50 – 1,094.111,045.0036% overvaluedDCF · EBITDA exit · 10y1,025.85 – 1,218.451,117.4427% overvaluedP/E · peers600.83 – 1,327.09689.13106% overvaluedP/E · own history1,461.06 – 2,550.271,819.9322% undervaluedPEG—860.1165% overvaluedEV/EBITDA · peers597.34 – 1,002.56632.59124% overvaluedEV/Revenue · peers470.43 – 688.23569.69149% overvaluedEarnings power value114.04 – 191.30144.89878% overvaluedWall St. consensus target—1,450.002% belowCost of capital (WACC)—7.45%—
DCF · Perpetuity growth · 5y leads for a high-growth company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
943.85
Eli Lilly closed at $1,417.54 — overvalued by 50% vs model.
754.88the model's range1,243.04
DCF · Perpetuity growth · 5y leads for a high-growth company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
144.89 – 1,819.93
Wall St. target
1,450.00 2% below
Above model, 1y
28 of 31 days
How it is valued
Valued asHigh growth
High revenue growth (~38% recent)High profitability (32% net margin)Highly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.